Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.

Molecular cancer research : MCR - 1 Apr 2015

Okamoto Koichi, Zaanan Aziz, Kawakami Hisato, Huang Shengbing, Sinicrope Frank A

Abstract excerpt

UNLABELLED: KRAS mutations are frequently detected in human colorectal cancer and contribute to de novo apoptosis resistance and ultimately therapeutic failure. To overcome KRAS-mediated apoptosis resistance, the irreversible proteasome inhibitor, carfilzomib, was evaluated and found to potently induce Noxa, which was dependent upon c-Myc, and Bik. Isogenic mutant versus wild-type KRAS carcinoma cells showed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Apoptosis Regulatory Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to bcl-X Protein

Share to Colonic Neoplasms

Share to Drug Synergism

Share to Oligopeptides

Share to Proto-Oncogene Proteins c-bcl-2

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 25548100
DOI: 10.1158/1541-7786.MCR-14-0476
PMCID: PMC4398608

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.PMID 25548100Read ↗

Bcl-xL is a key mediator of apoptosis following KRAS <sup>G12C</sup> inhibition in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant colorectal cancerSemantic proximity Read ↗

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.Semantic proximity Read ↗

mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.Semantic proximity Read ↗

Bcl-xL is an oncogenic driver in colorectal cancer.Semantic proximity Read ↗

CRISPR screens identify a novel combination treatment targeting BCL-XL and WNT signaling for KRAS/BRAF-mutated colorectal cancers.Semantic proximity Read ↗

BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancerSemantic proximity Read ↗

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.Semantic proximity Read ↗

A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers.Semantic proximity Read ↗

Targeting antioxidant enzymes enhances the therapeutic efficacy of the BCL-XL inhibitor ABT-263 in KRAS-mutant colorectal cancers.Semantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic BirinapantSemantic proximity Read ↗

BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.